secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2026-05-11T20:08:24+00:00
Accession:  0001193125-26-216758
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana Q1 net loss $47.2M, cash $101.1M; Mayo $25M equity; SC451/SG293 trials on track for 2026
--------------------------------------------------------------------------------

- Net loss of $47.2M ($0.17/sh); R&D expenses $28.7M (down from $37.2M YoY).
- Cash & securities $101.1M; pro forma $128.9M including Mayo $25M equity and ATM activity.
- Mayo collaboration to accelerate SC451; Mayo made $25M equity investment with option for another $25M.
- SC451 Phase 1 IND filing expected later this year; SG293 clinical data presented May 12 at ASGCT.
- SG227 (BCMA CAR) expected to begin clinical testing as early as mid-2027, contingent on SG293 data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000119312526216758/0001193125-26-216758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000119312526216758/sana-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-216758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer